This take in one's arms launch may hold forward-looking statements concerning, in the midst Other things, Northfield's prospective business plans and strategies and clinical and regulatory developments affecting our PolyHeme red Blood stall stand-in Product. These forward-looking statements are identified by the use of such terms as "intends," "expects," "plans," "estimates," "anticipates," "should," "believes" and equivalent terms. These forward-looking statements betoken hereditary risks and uncertainties.
Our realistic results may therefore fall out substantially from those predicted by the forward-looking statements because of various factors and accomplishable events, including the odds that FDA may jilt our BLA concession as fragmentary or otherwise not in compliance with applicable FDA regulations, the plausibility that FDA, even if it accepts our BLA for filing, will not present our requisition for Priority Review, the possibility that even if Priority Review is granted, FDA may not gratify the required period periods for the assess of our BLA under applicable laws and regulations, our latent inability to obtain FDA consent to market PolyHeme commercially based on our BLA, our possibility unqualifiedness to regain compliance with applicable Nasdaq listing standards, our want to possession of additional capital to finance our uninterrupted business operations and the construction of an expanded commercial-scale manufacturing facility, our embryonic impotence to obtain adequate supplies of inexperienced materials and to manufacture PolyHeme in commercial quantities, our budding incapability to market PolyHeme successfully, the prospect that competitors will develop Products that will reword PolyHeme obsolete or non-competitive, our potency inability to protect our intellectual resources rights, the outcome of a purported form action lawsuit as described in our most recently filed every three months report on Form 10-Q, the conceivability that we may be subject to fallout liability claims and Other legal actions, our dependency on a minimal number of mood personnel, the uncertainty of third wingding reimbursement for our Product and Other risks and uncertainties described from opportunity to time in our periodical reports filed with the Securities and Exchange Commission, including our most recently filed annual shot on Form 10-K and four times a year gunshot on Form 10-Q. These forward-looking statements use only as of the era of this press release. We do not bear the responsibility for any obligation to update or publicly put out any revisions to forward-looking statements to throw back events, circumstances or changes in expectations after the age such statement is made. All resulting written and viva voce forward-looking statements attributable to Northfield or any mortal acting on our behalf are well-informed by this cautionary statement.
Read the very informative article: click here
(more...)
Related posts
